Moody Lynn & Lieberson LLC Has $1.46 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Moody Lynn & Lieberson LLC lifted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 63.0% during the 4th quarter, Holdings Channel reports. The firm owned 22,000 shares of the biotechnology company’s stock after buying an additional 8,500 shares during the quarter. Moody Lynn & Lieberson LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,461,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Marex Group plc bought a new stake in Arrowhead Pharmaceuticals during the second quarter worth about $576,000. Nordea Investment Management AB raised its stake in shares of Arrowhead Pharmaceuticals by 74.5% in the third quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company’s stock valued at $12,661,000 after acquiring an additional 158,937 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after acquiring an additional 2,096,238 shares during the last quarter. HBK Sorce Advisory LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $2,823,000. Finally, Erste Asset Management GmbH boosted its holdings in shares of Arrowhead Pharmaceuticals by 55.3% in the 3rd quarter. Erste Asset Management GmbH now owns 73,000 shares of the biotechnology company’s stock worth $2,466,000 after acquiring an additional 26,000 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $62.70 on Wednesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. The stock has a market capitalization of $8.78 billion, a P/E ratio of 40.98 and a beta of 1.23. The company’s 50 day simple moving average is $62.69 and its 200-day simple moving average is $54.23. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.38). The company had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The business’s revenue for the quarter was up 10461.3% on a year-over-year basis. During the same quarter last year, the firm earned ($1.39) EPS. Sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

ARWR has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, February 6th. The Goldman Sachs Group increased their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, January 7th. Piper Sandler restated an “overweight” rating and issued a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Finally, Bank of America lifted their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $81.67.

Insider Activity

In related news, insider James C. Hamilton sold 40,164 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $2,534,750.04. Following the transaction, the insider owned 171,958 shares in the company, valued at $10,852,269.38. This trade represents a 18.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Patrick O’brien sold 49,493 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $3,123,503.23. Following the completion of the sale, the chief operating officer owned 474,908 shares of the company’s stock, valued at approximately $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 112,844 shares of company stock valued at $7,171,814 over the last 90 days. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.